Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| RCTs | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This is a prospective observational national (France) study with 2 visits 3 months apart (baseline and 12 weeks after TNF alpha blockers initiation). The objective of recruitment is 500 SpA patients (diagnosis according to their treating rheumatologist) initiating a TNF alpha blocker.
The main objective of the study is to evaluate the impact of a concomitant fibromyalgia on the anti-TNF treatment effect in axial Spondyloarthritis in both anti-TNF naïve and pre-exposed patients.
Background: Diagnosis of SpA in the absence of objective signs of inflammation or structural damage can be challenging, and especially difficult to differentiate from Fibromyalgia. Furthermore, such patients can easily be classified as active and refractory to NSAIDs, and inappropriately receive TNF alpha blockers.
Objective: Primary objective: To evaluate the impact of fibromyalgia in the TNF alpha treatment effect in axial Spondyloarthritis in both anti-TNF naïve and - experienced patients.
Methods: Design: Prospective observational national (France) study with 2 visits 3 months apart (baseline and 12 weeks after TNF alpha blockers initiation). Patients: 500 SpA patients (diagnosis according to their treating rheumatologist) initiating a TNF alpha blocker. Data collection: items permitting the calculation of the ASAS criteria, the FIRST questionnaire (Fibromyalgia Rapid Screen Test), patients and disease characteristics, disease activity and severity items, and the domain leading the doctor's decision for initiating the TNF alpha blocker (CRP/Imaging/Symptoms) will be collected at baseline. Effectiveness measures (e.g. BASDAI and patient's global) and the doctor's decision to continue/discontinue the TNF alpha blocker will be collected during the second visit. Statistical analysis: for the main objective, evaluation of the predictive factors of a TNF alpha response in real life, and the impact of Fibromyalgia in such response (e.g. logistic regression to estimate BASDAI reduction of 50%). For the secondary objectives: evaluation of the relative attributable risks of the doctor's domains leading the TNF alpha blocker initiation (Imaging/CRP/Symptoms) in order to explain the anti-TNF therapy response; evaluation of the concordance existing between the current recommendations and the daily practice.
Expected results: A positive finding might results into a change in the way of managing patients (e.g. carefully checking for the co-existence of fibromyalgia before confirming a spondyloarthritis diagnosis, an active disease and also before initiating a specific therapy such as biologics.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fibromyalgia patients |
| ||
| Not fibromyalgia patients |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Follow-up after 12 weeks after TNF alpha blockers initiation | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| To Evaluate the Presence of Fibromyalgia (Defined by a FIRST Questionnaire >= 5/6) as a Predisposing Factor for Lower Treatment Response Rates to TNF Alpha Blockers | The difference in BASDAI50 response at week 12 between the patients with and those without fibromyalgia. | At 12 weeks after TNF alpha blockers initiation |
| Measure | Description | Time Frame |
|---|---|---|
| The Relative Attributable Risks of the Doctor's Reported Outcomes Versus the Patients Reported Outcomes in the Decision to Initiate/Switch Anti-TNF Therapy | At 12 weeks after TNF alpha blockers initiation | |
| Pourcentage of Patients With Fibromyalgia (as Co-morbidity or as Single Disease) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients suffering from SpA based on the opinion of the treating rheumatologist initiating a TNF alpha blocker.
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36573318 | Derived | Hamitouche F, Lopez-Medina C, Gossec L, Perrot S, Dougados M, Molto A. Evaluation of the agreement between the ACR 1990 fibromyalgia tender points and an enthesitis score in patients with axial spondyloarthritis. Rheumatology (Oxford). 2023 Aug 1;62(8):2757-2764. doi: 10.1093/rheumatology/keac683. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Fibromyalgia Patients | 202 (38.4%) according to the FiRST questionnaire. |
| FG001 | Not Fibromyalgia Patients | 324 (61.6%) according to the FiRST questionnaire |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| At 12 weeks after TNF alpha blockers initiation |
| Evaluation of the Concordance Existing Between the Current Recommendations for the Initiation of Anti-TNF in Non-radiographic Axial SpA and the Daily Practice as Represented by This Study. | At baseline and at 12 weeks after TNF alpha blockers initiation |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Fibromyalgia Patients | According to the FiRST Questionnaire Follow-up after 12 weeks after TNF alpha blockers initiation |
| BG001 | Not Fibromyalgia Patients | According to the FiRST Questionnaire Follow-up after 12 weeks after TNF alpha blockers initiation |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | To Evaluate the Presence of Fibromyalgia (Defined by a FIRST Questionnaire >= 5/6) as a Predisposing Factor for Lower Treatment Response Rates to TNF Alpha Blockers | The difference in BASDAI50 response at week 12 between the patients with and those without fibromyalgia. | Posted | Number | participants | At 12 weeks after TNF alpha blockers initiation |
|
|
| ||||||||||||||||||||||||||||||
| Secondary | The Relative Attributable Risks of the Doctor's Reported Outcomes Versus the Patients Reported Outcomes in the Decision to Initiate/Switch Anti-TNF Therapy | Not Posted | At 12 weeks after TNF alpha blockers initiation | Participants | |||||||||||||||||||||||||||||||||||
| Secondary | Pourcentage of Patients With Fibromyalgia (as Co-morbidity or as Single Disease) | Not Posted | At 12 weeks after TNF alpha blockers initiation | Participants | |||||||||||||||||||||||||||||||||||
| Secondary | Evaluation of the Concordance Existing Between the Current Recommendations for the Initiation of Anti-TNF in Non-radiographic Axial SpA and the Daily Practice as Represented by This Study. | Not Posted | At baseline and at 12 weeks after TNF alpha blockers initiation | Participants |
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Fibromyalgia Patients | According to the FiRST Questionnaire Follow-up after 12 weeks after TNF alpha blockers initiation | 0 | 202 | 0 | 202 | ||
| EG001 | Not Fibromyalgia Patients | According to the FiRST Questionnaire Follow-up after 12 weeks after TNF alpha blockers initiation | 0 | 324 | 0 | 324 |
Not provided
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Doctor Anna MOLTO | Rheumatology department, Cochin Hospital, APHP | 0158412617 | anna.molto@aphp.fr |
| ID | Term |
|---|---|
| D000089183 | Axial Spondyloarthritis |
| D005356 | Fibromyalgia |
| ID | Term |
|---|---|
| D025242 | Spondylarthropathies |
| D025241 | Spondylarthritis |
| D013166 | Spondylitis |
| D013122 | Spinal Diseases |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D000844 | Ankylosis |
| D007592 | Joint Diseases |
| D001168 | Arthritis |
| D009135 | Muscular Diseases |
| D012216 | Rheumatic Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| >=65 years |
|
| Male |
|